Discovery+ usa的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到下列股價、配息、目標價等股票新聞資訊

Nuclear Receptors: The Art and Science of Modulator Design and Discovery

為了解決Discovery+ usa的問題，作者 這樣論述：

Dr. Mostafa Z. Badr is a Professor Emeritus at the University of Missouri-Kansas City, USA. Dr. Badr obtained his Bachelor degree in Pharmacy and a Master’s degree in Organic Chemistry from the Faculty of Pharmacy, Cairo University, Egypt. Dr. Badr subsequently obtained a Ph.D. Degree in Pharmacolog

y and Toxicology from the University of Louisville, after which he received postdoctoral training in Toxicology at the University of North Carolina-Chapel Hill. In 1987 Dr. Badr accepted the position of Assistant Professor at the University of Missouri-Kansas City School of Pharmacy, where he retire

d as Professor in 2015. Dr. Badr has authored and co-authored over 70 publications in peer-reviewed journals, and has published three previous books with Springer Nature. Dr. Badr founded the journal of PPAR Research and served as its Editor-in-Chief from 2005-2011, and the journal of Nuclear Recept

or Research and served as its Editor-in-Chief from 2013 until 2019.Mostafa Badr, Ph.D.Kansas City, MO, USANovember 2020.

Discovery+ usa進入發燒排行的影片

An Integrated Approach For Uncovering Novel DNA Methylation Biomarkers For Non-small Cell Lung Carcinoma

為了解決Discovery+ usa的問題，作者VAIBHAV KUMAR SUNKARIA 這樣論述：

Introduction - Lung cancer is one of primal and ubiquitous cause of cancer related fatalities in the world. Leading cause of these fatalities is non-small cell lung cancer (NSCLC) with a proportion of 85%. The major subtypes of NSCLC are Lung Adenocarcinoma (LUAD) and Lung Small Cell Carcinoma (LUS

C). Early-stage surgical detection and removal of tumor offers a favorable prognosis and better survival rates. However, a major portion of 75% subjects have stage III/IV at the time of diagnosis and despite advanced major developments in oncology survival rates remain poor. Carcinogens produce wide

spread DNA methylation changes within cells. These changes are characterized by globally hyper or hypo methylated regions around CpG islands, many of these changes occur early in tumorigenesis and are highly prevalent across a tumor type.Structure - This research work took advantage of publicly avai

lable methylation profiling resources and relevant comorbidities for lung cancer patients extracted from meta-analysis of scientific review and journal available at PubMed and CNKI search which were combined systematically to explore effective DNA methylation markers for NSCLC. We also tried to iden

tify common CpG loci between Caucasian, Black and Asian racial groups for identifying ubiquitous candidate genes thoroughly. Statistical analysis and GO ontology were also conducted to explore associated novel biomarkers. These novel findings could facilitate design of accurate diagnostic panel for

practical clinical relevance.Methodology - DNA methylation profiles were extracted from TCGA for 418 LUAD and 370 LUSC tissue samples from patients compared with 32 and 42 non-malignant ones respectively. Standard pipeline was conducted to discover significant differentially methylated sites as prim

ary biomarkers. Secondary biomarkers were extracted by incorporating genes associated with comorbidities from meta-analysis of research articles. Concordant candidates were utilized for NSCLC relevant biomarker candidates. Gene ontology annotations were used to calculate gene-pair distance matrix fo

r all candidate biomarkers. Clustering algorithms were utilized to categorize candidate genes into different functional groups using the gene distance matrix. There were 35 CpG loci identified by comparing TCGA training cohort with GEO testing cohort from these functional groups, and 4 gene-based pa

nel was devised after finding highly discriminatory diagnostic panel through combinatorial validation of each functional cluster.Results – To evaluate the gene panel for NSCLC, the methylation levels of SCT(Secritin), FOXD3(Forkhead Box D3), TRIM58(Tripartite Motif Containing 58) and TAC1(Tachikinin

1) were tested. Individually each gene showed significant methylation difference between LUAD and LUSC training cohort. Combined 4-gene panel AUC, sensitivity/specificity were evaluated with 0.9596, 90.43%/100% in LUAD; 0.949, 86.95%/98.21% in LUSC TCGA training cohort; 0.94, 85.92%/97.37 in GEO 66

836; 0.91,89.17%/100% in GEO 83842 smokers; 0.948, 91.67%/100% in GEO83842 non-smokers independent testing cohort. Our study validates SCT, FOXD3, TRIM58 and TAC1 based gene panel has great potential in early recognition of NSCLC undetermined lung nodules. The findings can yield universally accurate

and robust markers facilitating early diagnosis and rapid severity examination.

Surgery for Ovarian Cancer

為了解決Discovery+ usa的問題，作者 這樣論述：

Robert E Bristow MD MBA is Professor and Chair of the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine - Medical Center in Orange, California, USA. Professor Bristow’s primary clinical and research interests include the surgical management o

f advanced-stage gynecologic cancer and the patterns of health care delivery for women with gynecologic cancer. Dr. Bristow is extensively published in the field of ovarian cancer surgical research and he is also a deputy editor of the journal Gynecologic Oncology.Beth Y Karlan MD is Director of the

Women’s Cancer Research Institute and the Division of Gynecologic Oncology at Cedars-Sinai Medical Center and Professor of Obstetrics and Gynecology at the David Geffen School of Medicine at the University of California, Los Angeles, California, USA. Professor Karlan’s research interests include mo

lecular biomarker discovery, inherited cancer susceptibility and translational research efforts focused towards innovative treatment strategies for ovarian cancer. She has served as President of the Society of Gynecologic Oncologists and in 2006 was named an American Cancer Society Early Detection C

linical Research Professor. Professor Karlan is the Editor-in-Chief of Gynecologic Oncology.Dennis S Chi MD is Professor and Deputy Chief of the Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. Dr Chi’s primary research interests include the

correlation of radiographic evaluation and operative findings in gynecologic malignancies and the utilization of innovative and advanced surgical techniques to improve outcomes for women with early, advanced, or recurrent gynecologic cancers. He is on the editorial board of the journals Journal of

Oncology and The Oncologist and has served as the president of the Society of Memorial Gynecologic Oncologists and the Metropolitan Gynecologic Cancer Society.

以紫外線傷害之表現質體探討水溫上升對斑馬魚胚胎DNA切割修補作用之影響

為了解決Discovery+ usa的問題，作者西莉亞 這樣論述：

由於核電站排放的加熱污水或海洋變暖，海水溫度可能會升高。在接收排放的海洋區域，發現溫度升高了 8 至 12 攝氏度，高於環境溫度。核苷酸切除修復 (NER) 通過去除螺旋扭曲的 DNA 損傷來保護遺傳材料的完整性。本研究旨在探討斑馬魚胚胎中 NER 對水溫升高的閾值敏感性。將受精後 10 小時 (hpf) 的早期胚胎和在 28.5 ˚C 飼養的 24 hpf 的中早期胚胎迅速轉移到預熱至 37、33 或 31 ˚C 的水中 30 分鐘，並通過帶移測定法測定 NER 活性和體外 DNA 修復試驗。紫外線誘導形成兩種類型的螺旋扭曲損傷，稱為環丁烷嘧啶二聚體 (CPD) 和 (6-4) 光產物 (

6-4PP)。帶移測定顯示在 10 hpf 胚胎中受到 +8.5 ˚C 熱應激的刺激 6-4 PP 結合活動，但這些活動在壓力 24 hpf 胚胎中受到抑制。熱應激對 CPD 檢測活動產生了類似的影響。在經歷 + 4.5 ˚C 弱熱應激 (WHS) 的胚胎中也觀察到 6-4 PP 和 CPD 結合活性的增強。相比之下，紫外線損傷的 DNA 結合活性在 WHS 下的中早期胚胎中受到抑制。 CPD 和 6-4PP 傳感活動在早期和中期早期胚胎中在 + 2.5 ˚C 溫和熱應激 (MHS) 中均受到抑制，並且抑制紫外線損傷的 DNA 結合活動與抑制整體 NER 相關通過基於轉錄的修復測定確定的容量，

揭示了斑馬魚胚胎中 NER 機制對 MHS 的易感性，無論發育階段如何。因此，當水溫升至 2.5 ˚C 時，魚胚胎也無法保持其遺傳完整性。